Saturday 17 October 2026 Export NRIX’s income statement to Excel — free account

Nurix Therapeutics, Inc.

Nurix Therapeutics, Inc.’s revenue for fiscal 2025 (year ended November 2025) was $84.0 million, up 54.0% from fiscal 2024. In the quarter to August 2026, revenue grew 8,426.3%, EPS grew 578.5% and free cash flow grew 1,122.1%, each against the same quarter a year earlier.

24.42 0.53 −2.12%

Follow NRIX

Alert me

Market cap: $2.7B
P/E: 9.7×
Fwd P/E: −4.9×
Dividend yield: —
F-score: 4/9
Altman Z: 3.77
Beneish M: n/a
Dividend safety: n/a

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Total sells 5.09

Totals in millions of $.

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	—	—	—	—	—	—	—	—	—	—	—	—
Sell	2	1	4	1	1	4	3	3	4	4	2	3

Insider Ownership 11.40%

Capital & Financial Ratios $m

Market Cap 2,730.00

Revenue 701.94

Net Income 294.88

Free Cash Flow 369.81

Net Debt (1,048.25)

Current Ratio 8.44

Debt/Equity 0.00

P/E ratio 9.74

Fwd P/E (4.94)

P/S ratio 3.88

P/B ratio 2.81

Past 5Y EPS Growth —

This Y EPS Growth 162.24%

Next Y EPS Growth (210.70%)

Next Y revenue growth 799.38%

Next 5Y EPS Growth 32.31%

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years

P/S against its own 10 years 1.56%

10-year low 10-year high

P/B against its own 10 years 60.26%

10-year low 10-year high

EV/Sales against its own 10 years 5.47%

10-year low 10-year high

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

	total	individual payouts
2023	Powerpack
2022	Powerpack
2021	Powerpack
2019	Powerpack

special payouts not included in total or ratios

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	288	610	593	1,048
Receivables	—	—	—	20
Inventory	—	—	—	—
Other	—	—	—	—
	296	619	607	1,104

	2023	2024	2025	Q'26
Payables	6	11	11	33
ST’ Debt	—	—	—	—
Other	—	—	—	22
	87	96	86	131

Compound Annual Growth %

	10y	5y	3y
Sales	—	36.35%	29.55%
Cash Flow	—	0.00%	0.00%
Earnings	—	0.00%	0.00%
Book Value	—	13.17%	21.05%

Revenue $m

	Feb	May	Aug	Nov	Year
’26	6	9	673	—	—
’25	18	44	8	14	84
’24	17	12	13	13	55
’23	13	31	18	15	77
’22	10	11	11	7	39
’21	5	7	10	7	30
’20	3	4	4	7	18

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Feb	May	Aug	Nov	Year
’26	(72)	(97)	616	—	—
’25	(61)	(63)	(57)	(68)	(249)
’24	(42)	(40)	(42)	(49)	(173)
’23	(48)	(18)	(41)	27	(81)
’22	(43)	(33)	(46)	(38)	(160)
’21	8	(32)	(30)	(31)	(84)
’20	41	(14)	(6)	(20)	0

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Feb	May	Aug	Nov	Year
’26	(73)	(99)	614	—	—
’25	(65)	(66)	(60)	(73)	(263)
’24	(45)	(42)	(45)	(51)	(182)
’23	(51)	(20)	(44)	24	(90)
’22	(46)	(36)	(50)	(41)	(172)
’21	7	(34)	(32)	(32)	(90)
’20	41	(16)	(8)	(21)	(5)

Fiscal quarters ending in the months shown.

EPS $

	Feb	May	Aug	Nov	Year
’26	(0.79)	(0.81)	4.73	—	—
’25	(0.67)	(0.52)	(1.03)	(0.82)	(3.05)
’24	(0.76)	(0.71)	(0.67)	(0.75)	(2.88)
’23	(0.75)	(0.45)	(0.68)	(0.77)	(2.65)
’22	(0.95)	(1.01)	(0.90)	(0.87)	(3.71)
’21	(0.63)	(0.60)	(0.65)	(0.85)	(2.73)
’20	(3.50)	1.54	(1.09)	(0.51)	(2.76)

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026e
Price, $
Price, $	Low	—	—	—	—	15.21	21.53	7.52	4.22	7.65	8.18	Analyst estimates 2026–2028 Powerpack
	High	—	—	—	—	52.38	51.46	30.52	13.99	29.56	22.50
People
People	Employees	—	—	—	103	135	242	297	284	286	317
	Revenue/emp, $m	—	—	0.00	0.30	0.13	0.12	0.13	0.27	0.19	0.26
Income, $m
Income, $m	Revenue	—	—	37	31	18	30	39	77	55	84
	Gross margin, %	—	—	100.00	100.00	100.00	100.00	100.00	100.00	100.00	100.00
	EBT	—	—	(9)	(21)	(64)	(117)	(180)	(144)	(193)	(264)
	EBT margin, %	—	—	(23.82)	(68.97)	(357.90)	(393.49)	(466.93)	(186.98)	(354.36)	(314.00)
	Net income	—	0	(9)	(22)	(43)	(117)	(180)	(144)	(194)	(264)
	Depreciation	—	—	3	2	2	8	11	8	5	9
Per share, $
Per share, $	Revenue	—	—	13.29	9.45	1.14	0.69	0.79	1.42	0.81	0.97
	Earnings	—	—	(3.35)	(6.59)	(2.76)	(2.73)	(3.71)	(2.65)	(2.88)	(3.05)
	Cash flow	—	—	(11.24)	0.18	(0.01)	(1.97)	(3.29)	(1.50)	(2.57)	(2.88)
	Capex	—	—	(0.56)	(0.50)	(0.29)	(0.13)	(0.25)	(0.15)	(0.14)	(0.16)
	Free cash flow	—	—	(11.81)	(0.32)	(0.30)	(2.10)	(3.54)	(1.65)	(2.71)	(3.04)
	Book value	—	—	(13.08)	(17.53)	18.52	7.98	6.25	3.69	7.85	6.22
	Shares, m	—	—	3	3	16	43	49	54	67	87
Valuation, ×
Valuation, ×	P/E	—	—	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	P/S	—	—	0.00	0.00	37.49	41.55	15.59	4.39	26.44	17.45
	P/B	—	—	0.00	0.00	2.30	3.61	1.98	1.69	2.74	2.72
	EV/Sales	—	—	0.00	0.00	21.71	31.61	7.59	0.65	15.27	10.39
	EV/FCF	—	—	(2.19)	(2.19)	(83.50)	(10.45)	(1.70)	(0.56)	(4.58)	(3.31)
Cash, $m
Cash, $m	Operating cash flow	—	—	(32)	1	0	(84)	(160)	(81)	(173)	(249)
	Capex	—	—	(2)	(2)	(5)	(6)	(12)	(8)	(9)	(14)
	Free cash flow	—	—	(33)	(1)	(5)	(90)	(172)	(90)	(182)	(263)
Balance, $m
Balance, $m	Working capital	—	—	8	23	254	245	248	209	524	520
	Total debt	—	—	—	—	—	13	12	—	—	—
	Net debt	—	—	(39)	(38)	(281)	(296)	(309)	(288)	(610)	(593)
	Shareholders’ equity	—	—	(37)	(58)	290	342	304	200	527	539
Returns, %
Returns, %	ROA	—	—	(41.54)	(48.52)	(19.64)	(26.85)	(40.37)	(37.27)	(37.77)	(38.96)
	ROIC	—	—	0.00	0.00	(445.28)	(158.17)	0.00	0.00	0.00	0.00
	ROE	—	—	19.94	45.89	(37.19)	(37.05)	(55.84)	(57.10)	(53.22)	(49.63)

Negative figures in brackets.

All 10 years →

Fiscal years to Nov 2025 · latest quarter Aug 2026 · fundamentals updated 15 Oct 2026

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
CELC Celcuity, Inc.	$3.0B	— (loss-making)	—	—	n/m	−53.27% (below 0%: shrinking)	0.00%	0.00%	Compare
DNLI Denali Therapeutics Inc.	$2.9B	— (loss-making)	— (loss-making)	−89.74% (below 0%: shrinking)	n/m	−22.91% (below 0%: shrinking)	97.42%	(3,622.11%)	Compare
RCUS Arcus Biosciences, Inc.	$2.9B	— (loss-making)	— (loss-making)	−74.38% (below 0%: shrinking)	n/m	+10.53% (above 0%: growing)	100.00%	(234.15%)	Compare
ELVN Enliven Therapeutics, Inc.	$2.9B	— (loss-making)	—	—	n/m	−8.34% (below 0%: shrinking)	0.00%	0.00%	Compare
DYN Dyne Therapeutics, Inc.	$2.9B	— (loss-making)	—	—	n/m	−39.08% (below 0%: shrinking)	0.00%	0.00%	Compare
NRIX Nurix Therapeutics, Inc.	$2.7B	9.7×	— (loss-making)	+8,426.27% (above 0%: growing)	n/m	+1,122.10% (above 0%: growing)	100.00%	83.12%
ZLAB Zai Lab Limited Unsponsored ADR	$2.7B	— (loss-making)	— (loss-making)	−3.33% (below 0%: shrinking)	n/m	−84.42% (below 0%: shrinking)	54.70%	(71.95%)	Compare
PGEN Precigen, Inc.	$2.6B	— (loss-making)	— (loss-making)	+6,322.66% (above 0%: growing)	n/m	+8.73% (above 0%: growing)	94.90%	41.18%	Compare
BEAM Beam Therapeutics Inc.	$2.6B	— (loss-making)	— (loss-making)	−94.21% (below 0%: shrinking)	n/m	+13.92% (above 0%: growing)	100.00%	(25,827.14%)	Compare
Median of peers	$2.9B	—	—	−74.38%	—	−15.62%	74.80%	(35.97%)

All 614 Biotechnology stocks →

Nurix Therapeutics, Inc. (NRIX) key facts

Strength: Nurix Therapeutics, Inc.’s revenue for fiscal 2025 (year ended November 2025) was $84.0 million, up 54.0% from fiscal 2024.
Nurix Therapeutics, Inc. (NRIX) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
As of October 16, 2026, NRIX traded at $24.42, a market capitalization of $2.7 billion.
Return on equity was −49.6% and debt-to-equity 0.00.
Its Piotroski F-score is 4 out of 9 and its Altman Z-score is 3.77 (safe zone) for fiscal 2025.

Source: company filings (standardised) and stockrow calculations · fundamentals updated Oct 15, 2026.